

# Index

Page numbers in italics indicate items in tables

- AACD (age-associated cognitive decline), 7, 12, 16
- AAMI (age-associated memory impairment), 7, 16
  - prevalence, 10
- abulia, 77
- activities
  - leisure, life satisfaction and, 2
  - of daily living
    - assessment for AD, 64
    - CSI-D assesses, 68
    - diagnosis and, 8, 15, 32
    - instrumental, 79
    - managing, 119
    - MCI, 10, 20
  - social
    - AD, 76
    - life satisfaction and, 2
  - therapeutic, 95, 118
- acupuncture, 149
- AD (Alzheimer’s disease)
  - 10/66 Dementia Research Group study, 177
  - African Americans, 27–9
  - agitation/aggression, 79
  - anxiety in, 78
  - BPSD in, 75
  - CDR in, 8
  - China, 149
  - comparative studies in, 63
  - depression in, 75
  - diet and, 57
  - differentiating from MCI, 10
  - features, 82
  - management in Australia, 133
  - mixed dementia, 34, 39
  - pre-, 8
  - prevalence, 39, 40, 107
    - ethnicity and, 93
    - USA, 137
  - psychosis in, 80
  - VaD and, 41
- adaptation of test instruments, 65–9, 95
- ADAS-Cog, 32
  - Australia, 132, 133
  - China, 149
- ADI (Alzheimer’s Disease International), 153–8, 160–2, 163
  - Lancet* and, review of dementia prevalence, 165–6
- ADRQL (Alzheimer’s Disease-Related Quality of Life), 90
- advocacy, 175
  - China, 111
  - rural areas, 115
- AES (Apathy Evaluation Scale), 77
- Africa
  - dementia prevalence, 168, 171
  - 10/66 Dementia Research Group study, 65, 164
  - South
    - 10/66 Dementia Research Group study, 166
- African Americans
  - AD and dementia, 27–9
  - caregivers, 92, 95
  - comparative studies in, 64
  - CSI-D adapted for, 65
  - dementia incidence and prevalence, 43
  - vascular disease, 28
- age
  - AD and, 40
  - associated cognitive decline (AACD), 7, 12, 16
  - associated memory impairment (AAMI), 7, 16
    - prevalence, 10
  - cardiovascular disease and, 38
  - consistent memory impairment, 7
  - estimation, 94
  - perception of old, cultural differences, 1–2, 3, 92–3
  - related changes in memory, 7

Index

- age (cont.)
  - specific incidence
    - dementia, 27
    - VaD and, 38, 40
- aggression, 73, 75, 78–9
  - scale, 75
- aging
  - brain
    - fatty acids and, 57
    - oxidative stress and, 57
  - cultural perspective, 92–3, 115, 124, 127, 150
    - Asia, 1–2
    - India, 175
- Agitated Behavior Inventory for Dementia, 75
- agitation, 78–9
  - MCI, 10
  - Parkinson’s disease, 81
  - scale, 75
- agnosia, 65
  - caregiver, 103
- AIDS dementia complex, 48–9
- albendazole, 52
- alcohol, VaD, 38
- algorithm
  - 10/66 Dementia Research Group, 65, 93, 124, 164, 177
  - diagnosis of MCI, 9
- alpha blockers, 149
- Alzheimer associations, 153–8, 160–2, 175
- Alzheimer Café, 154
- Alzheimer’s disease. *See* AD
- Alzheimer’s Disease International (ADI), 153–8, 160–2, 163
  - Lancet and, review of dementia prevalence, 165–6
- Alzheimer’s Disease-Related Quality of Life, 90
- America
  - attitudes of caregivers in, 76, 95
  - dementia prevalence, 168, 170
  - depression, 3
  - Latin, 10/66 Dementia Research Group study, 65, 164, 166, 172
  - perception of symptoms, 73
  - prevalence studies in, 166
  - tolerance of symptoms, 76
  - United States
    - AD and dementia, 27–9, 137–9
    - care in, 94
    - dementia, 27
    - prevalence studies in, 167
- amlodipine, 18
- amnesic syndrome, 7
- amyloid
  - markers, MCI, 11
  - PET, 139
- anhedonia, 76, 77
- aniracetam, 18
- anosognosia, 80, 89
- antidepressants, 148, 149
- anti-inflammatories, 18
- antioxidants, 18, 56, 57, 149
- antipsychotics, 148, 149
- anti-retroviral therapy, 49, 50
- antituberculous medication, 51
- anxiety, 73, 75, 78, 172
  - caregivers’, 4, 100
  - GAD, 78
  - MCI, 10
  - Parkinson’s disease, 81
  - scale, 75
- anxiolytics, 148, 149
- apathy, 76–8, 79, 81
  - cultural background and, 73
  - HIV and, 48
  - MCI, 10
  - Parkinson’s disease, 81
- Apathy Evaluation Scale, 77
- Apathy Inventory, 77
- Apathy Scale, 75
- aphasia, 65
- APOE4, 14, 17, 28, 64
- apraxia, 65
- arachnoiditis, tuberculosis and, 51
- Argentina, 10/66 Dementia Research Group study, 176
- arteritis
  - dementia caused by, 49
  - tuberculosis and, 50
- Asia
  - apathy, 76
  - care in, social change and, 4
  - caregivers in, 4
  - dementia prevalence, 168, 170
  - demography, 1
  - depression, 3
  - perception of old age in, 1–2
  - prevalence studies in, 166
    - 10/66 Dementia Research Group study, 65, 164
  - South, attitudes of UK immigrants from, 94
  - stroke, 38
  - VaD, 80

- aspirations
  - life satisfaction and, 2
  - old age, 1
- assessment. *See also* measurement and instruments
  - cross-cultural, 63–9
  - frontal, executive, and subcortical function, 32
  - memory, 4
  - multi-linguistic societies, 48
  - services, Australia, 132–3
  - single-domain, 75
- ataxia, cerebellar in CJD, 52
- atrophy, focal, 8
- attention, 77
  - cognitive domain, 7
  - drug effects, 18
  - HIV and, 48
- attitudes
  - caregivers', 4
    - America, 76, 95
    - India and China, 102
  - different
    - affect access to medical help, 92
    - affect diagnosis, 15, 39
    - to mental illness, 94
    - to old age, 1–2, 92–3
    - to dementia, 174
      - America, 92
- Australia
  - dementia and care in, 131–4
  - dementia prevalence, 170
  - prevalence studies in, 166, 167
  - tolerance of symptoms, 73
- awareness
  - LAMIC, 174
  - raising, 153–8, 159–62, 175
- balance, MCI and, 10
- BEHAVE-AD (Behavioral Pathology in Alzheimer Disease Rating Scale), 74, 75, 78
- behavior
  - aberrant motor, MCI, 10
  - attitude and, 92
  - health seeking, 3
  - risky, influences on, 3
  - therapy, MCI, 18
- behavioral
  - dysfunction, measures of, 75
  - impairment, infection and, 47
  - symptoms
    - agitated/aggressive, 78–9
    - burden in Nigeria, 127
    - conversion and, 14
    - HIV, 48
    - MCI, 10
- Behavioral and Psychological Symptoms of Dementia. *See* BPSD
- Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVE-AD), 74, 75, 78
- Behavioral Rating Scale for Dementia (BRSD), 74, 75
- beliefs, cultural
  - affect diagnosis, 15
  - perception of old age and in Asia, 1–2
- benign senescent forgetfulness (BSF), 7
- biomarkers, 139
  - predictors of conversion, 14
- blindness, cortical in CJD, 52
- blunting, emotional, 77
  - HIV and, 49
- BPSD (Behavioral and Psychological Symptoms of Dementia), 73, 74, 83
  - in 10/66 Dementia Research Group study, 172
  - management, Australia, 133
  - reason for seeking medical attention, 127, 150
- brain
  - activity
    - MCI, 11
    - VCI, 32
  - at-risk, 34
- Brazil
  - epidemiological study, 94
  - prevalence studies in, 167
  - 10/66 Dementia Research Group study, 166
- BRSD (Behavioral Rating Scale for Dementia), 74, 75
- BSF (benign senescent forgetfulness), 7
- burden, caregivers, 79, 99–103, 162
  - depression in AD, 76
  - determinants of, 73
  - Japan, 143
  - Nigeria, 128
  - Peru, 125
  - psychosis, 80
  - symptoms, 94
- burnout
  - caregivers, 18
  - professionals, 114
- BVRT, predictor of conversion, 14

Index

- calcium channel blockers, 18, 149
- CAMCOG, 132
- campaigns, awareness, 153–8, 159–62
- Canada
  - CSI-D developed in, 65
  - prevalence of dementia, 39
- care. *See also* management, support, treatment
  - arrangements, 10/66 Dementia Research Group study of
  - China, 107–11, 150
  - England, 94
  - family
    - attitude to age and, 92
    - social change and, 4
  - models of, 116, 143, 144
  - Nigeria, 128
  - Peru, 124
  - Sweden, 94
  - USA, 94
- caregivers. *See also* family
  - attitudes of, 95, 175
  - burden, 79, 99–103, 162
    - depression in AD, 76
    - determinants of, 73
    - Japan, 143
    - Nigeria, 128
    - Peru, 125
    - psychosis, 80
    - symptoms, 94
  - distress in, 76, 82, 102, 118
  - education for, 160, 161, 175, 176
  - report of symptoms, 75, 77, 90
    - CDQLP, 90
  - social change and, 4
  - strain, 172
    - 10/66 Dementia Research Group study of, 172–4
  - stress in, 99–103, 162
    - aberrant motor behaviors and, 79
    - MCI, 18
    - measured, 90
    - symptoms, 4
  - support, 115, 154, 175
    - from family, 4, 160
    - groups, 120, 128, 154, 175
    - Sweden, 95
    - USA, 95
- Caribbean, 10/66 Dementia Research Group study, 65, 164
- CARITAS, World Health Organization, 113
- CDQLP (Community Dementia QoL Profile), 90
- CDR (Clinical Dementia Rating), 8, 12
- CERAD (Consortium to Establish an Alzheimer’s Registry) word task, 65, 164
- cerebrospinal fluid
  - MCI, 11, 14
  - neurocysticercosis, 51
  - neurological infection, 49, 50
  - neurotuberculosis, 51
- China
  - 10/66 Dementia Research Group study, 65, 164, 166, 172, 176
  - 10/66 intervention in, 177
  - beliefs and old age in, 1
  - caregivers’ attitudes in, 102
  - dementia
    - care, 107–11
    - diagnosis and treatment, 147–50
  - family support in, 172
  - perception of symptoms, 73
  - prevalence
    - of dementia, 39
    - studies in, 166, 167
  - stigma of dementia, 4
  - tolerance of symptoms, 73
  - traditional medicine, 2
- Chinese
  - CSI-D adapted for, 65
  - dementia prevalence, 93
  - depression, 4
  - life satisfaction, 2, 3
  - tolerance of symptoms, 76
- cholesterolemia, 38, 64
- cholinesterase, 139
- cholinesterase inhibitors, 15, 133, 148
- CILQ (Cognitively Impaired Life Quality Scale), 90
- CIND (Cognitive Impairment No Dementia), 12
  - NPI in, 81
  - prevalence, 10
  - stroke and, 9
- Clinical Dementia Rating (CDR), 8, 12
- CLOX test, 32
- cognitive
  - assessment, cross-cultural, 63–9
  - behavior therapy, in MCI, 18
  - change, measuring, 4
  - decline
    - age-associated, 7
    - apathy and, 77

- assessment, 65
- attitudes to, 91–3, 115
  - rural, 124
- education and, 28, 123
- global, 89
- imaging, 41
- infection and, 47
- leukoaraiosis, 32
- mood and, 3
- tuberculosis and, 51
- vascular risk factors, 56
- domains, 7
  - MCI, 10
- functioning
  - nutrition and, 55–8
  - Peru study, 123
  - quality of life and, 88
- impairment, 7
  - infection and, 47
  - mild.. *See* MCI
  - no dementia. *See* CIND
  - subjective (SCI), 19
  - VaD, 37
  - vascular, 31. *See* VCI
- intervention measures
  - MCI, 18
- reserve, 19
- Cognitive Impairment No Dementia (CIND), 12
- Cognitively Impaired Life Quality Scale (CILQ), 90
- Cohen-Mansfield Agitation Inventory, 75, 78
- community
  - changes affect support in old age, 2
  - services
    - Australia, 132
    - China, 109, 110, 111, 148
    - rural, 113–16
    - support from, in Asia, 5
  - support from, 175
  - Nigeria, 128
- Community Dementia QoL Profile (CDQLP), 90
- Community Screening Interview for Dementia. *See* CSI-D
- comorbidity
  - anxiety in, 78
  - apathy in, 76
  - caregiver strain and, 172–4
  - HIV infection, 51
  - mixed dementia, 34, 37, 39, 42
  - psychosis, 79
  - quality of life and, 89
  - treatment of in MCI, 18
- comparative studies, 40, 63–4, 172
  - impact of other chronic diseases, 174
  - Yoruba–African American, 28
- concentration
  - cognitive domain, 7
  - drug effects, 18
- confabulation, 80
- Consortium to Establish an Alzheimer’s Registry (CERAD) word task, 65, 164
- constructional ability, 65
- conversion
  - delayed recall as predictor of, 14
  - predictor, 11–15, 19
    - MCI as, 10, 11–15, 12, 16, 20
  - rates, 12, 17
  - SCI and, 19
- Cornell Scale for Depression in Dementia, 75
- counseling
  - caregivers, 101, 118
  - MCI, 18
- Cree Indians, CSI-D used in, 65
- Creutzfeldt–Jacob disease (CJD), 48, 52
- criteria
  - AAMI, 7
  - California, 31
  - dementia severity, 32
  - depression in AD, 76
  - diagnostic, 147
    - AD, 63
    - apathy, 77
    - CSI-D includes, 65
    - cultural influences, 15
    - dementia, 63
    - MCI, 8, 10, 12, 19, 64
    - mixed dementia, 34
    - NINCDS-ADRDA, 133
  - NINDS-AIREN, 31
  - psychosis, 80
  - VaD, 37, 39, 42–3
  - VCI, 31, 33, 34
- CSI-D (Community Screening Interview for Dementia), 64, 164
  - adaptation, 66
  - use of cross-culturally, 64–9
- CT
  - assessment, 132
  - cognitive decline, 41

- Cuba, prevalence studies in, 167
  - 10/66 Dementia Research Group study, 165, 166, 176
- cultures, different
  - access to health care and, 114
  - adapting test instruments for, 65–9, 133, 164
  - perceptions of quality of life, 91
  - perspectives on dementia, 91–3
    - affect diagnosis of VaD, 39
  - perspectives on old age, 92–3, 115, 124, 167
    - affect diagnostic criteria, 15
    - Asia, 1–2, 3
    - India and China, 103
  - reporting of symptoms in, 166, 167
- cysticercosis
  - as differential diagnosis, 47
  - neuro, 48, 51
- data archive, public, 10/66 Dementia study, 166
- day centers, Asia, 4
- delusions, 73, 75, 78, 79
- dementia
  - African Americans, 27–9
  - AIDS dementia complex, 47
  - apathy in, 77
  - care
    - China, 107–11
    - Japan, 141–5
    - Peru, 123–5
  - conversion rates, 12
  - diagnosis, 48
    - Japan, 144, 145
    - USA, 137–9
    - validity, 163–5
  - diagnosis and care
    - Australia, 134
    - China, 147–50
    - Nigeria, 127–9
  - disinhibition, 79
  - early-onset, 40
  - epidemiological studies, 10/66 Dementia Research Group, 163–77
  - epidemiology, 27, 93–4
    - China, 107
  - features, 82
  - frontotemporal (FTD), 8, 73, 82
  - GAD in, 78
  - HIV and, 48
  - incidence, 27, 43, 165
    - 10/66 Dementia Research Group study, 176
    - infection-associated, 47
  - late-onset, 40
  - Lewy body, 8, 73, 82
  - management, 117–20
  - MCI as predictor, 11–15, 16, 20
  - mild. *See also* MCI (mild cognitive impairment)
    - criteria for diagnosis, 8
  - mixed, 9, 34, 37, 39, 41
    - NPI in, 81
  - neurological infection, 47–53, 48
  - nutrition and, 55–8
  - prevalence, 39, 43, 170
    - China, 107
    - ethnic differences, 39, 93
    - impacts, 43
    - Peru, 124
    - studies, 165–8
    - USA, 137
  - prevention, 35
  - psychosis in, 79
  - quality of life, 264
  - reversible, 50, 52, 53
  - rural community services, 113–16
  - subclassification, 41, 43
  - syndrome, 43
- Dementia QoL (DQoL), 90
- Dementia Research Group, 10/66, 65, 93, 163–77
  - awareness raising, 158
  - Peru, 123, 124
  - prevalence studies, 166–7
- demography
  - Asia, 1, 5
  - Australia, 131
  - Brazil, 94
  - China, 107, 113
  - India, 113
  - Japan, 141
  - Peru, 123
  - prevalence of dementia and, 165
  - USA, 137
- demoralization, 78
- depression, 73, 75
  - AD and, 75
  - anxiety and, 78
  - apathy and, 76
  - caregivers', 4, 100, 125
  - comorbid, 18, 172
  - conversion and, 14

- disinhibition and, 79
- incidence, caregivers', 100
- MCI, 10
- Parkinson's disease, 81
- prevalence, 3
  - caregivers', 100
- scales, 75
- SCI, 20
- despair, 77
- diabetes
  - AD and, 28
  - VaD and, 37, 38
- diagnosis
  - AD, 63
  - cultural factors influencing
    - MCI, 15
    - Nigeria, 127, 128, 129
  - dementia, 41, 42–3, 48, 63
    - criteria, mild, 8
    - rural areas, 124
    - validity, 165
  - education and, 124
  - MCI, 10–11, 19
    - algorithm for, 9
  - mixed dementia, 34
  - neurosyphilis, 50
  - neurotuberculosis, 51
  - rate of in USA, 138
  - VaD, 37, 38, 39
  - VCI, 32, 34, 40
- digit–symbol substitution test in VCI, 32
- disability, dementia and, 174
- disinhibition, 76, 79
  - MCI, 10
- disorders, dysphoric or dysthymic, 9
- disorientation, therapies for, 119
- distress
  - caregivers', 102, 118
  - determinants of, 73
- distribution of disease, 63
- Dominican Republic
  - 10/66 intervention in, 177
  - family support in, 172
  - prevalence studies
    - 10/66 Dementia Research Group study, 166, 176
  - prevalence studies in, 167
- donepezil, 15, 128, 133, 148
- DQoL (Dementia QoL), 90
- drugs. *See also particular drugs and classes of drug*
  - MCI, 15, 19
- duty
  - filial
    - Asia, 2
    - China, 108
    - Korea, 92
    - view of in India and China, 102
- dyslipidemia, VaD and, 38
- dysphoria, 78
- dysregulation, behavioral, 75
- eating, 80
- ECAQ (Elderly Cognitive Assessment Questionnaire), 4
- economic change, effects on support in old age, 2, 108, 113, 159
- edema, cerebral, 52
- education
  - AD and, 28
  - assessment influenced by, 64, 89, 124, 164
  - caregivers, 18, 100–2, 117, 154, 160
    - Australia, 134
    - USA and Sweden, 95
  - cognitive decline and, 28, 123
  - cognitive reserve and, 19
  - community, 115
  - dementia and, 28, 55
  - for caregivers, 161, 176
  - life satisfaction and, 2
  - neuropsychological tests and, 28, 68
  - NGOs role, 154, 160–2
  - perception of old age and, 1
  - professionals, 154, 159, 161, 176, 177
    - Japan, 145
    - public, in China, 111
  - symptoms depend on, 73
  - testing influenced by, 93, 95
  - willingness to care and, 4
- EEG, in CJD, 52
- Elderly Cognitive Assessment Questionnaire (ECAQ), 4
- encephalitis
  - dementia caused by, 49
  - Herpes simplex, 47
  - Japanese B, 47
- England, care in, 94
- environmental factors
  - comparative studies of, 63
  - symptoms depend on, 73

- epidemiological studies
  - 10/66 Dementia Research Group, 163–77
  - comparative, 64–5
  - Peru, 123
- epidemiology
  - dementia, 27, 93–4
    - China, 107
  - MCI, 9, 16
  - nutrition in dementia, 57–8
  - VaD, 37, 39
  - VCI, 40
- estrogen, 18
- ethambutol, 51
- ethnicity
  - AD and, 28
  - incidence of dementia and, 27
  - life satisfaction and, 2
  - response to the elderly and, 3, 92
  - stroke and, 38
  - VaD and, 38, 39
- etiology
  - AD, in African Americans, 28
  - dementia, 174
  - VaD, 33, 37
  - VCI, 33
- euphoria in MCI, 10
- Eurasians, dementia prevalence, 93
- Europe
  - dementia prevalence, 39, 168, 170
    - 10/66 Dementia Research Group study, 166
  - studies in, 166
  - depression, 3
- European Alzheimer Disease Consortium, 80
- European consortium task-force, MCI syndrome, 8
- executive function
  - leukoaraiosis, 32
  - MCI, 10
  - VCI, 32
- exercise, 118
  - China, 148
  - health and, in Asia, 2
  - life satisfaction and, 3
- EXIT25 test, 32
- extrapyramidal features in CJD, 52
- FAB (Frontal Assessment Battery), 77
- facial emotion recognition, in MCI, 10
- falls, risk of
  - exercise and, 118
  - MCI and, 10
  - restraint and, 119
- family. *See also* caregivers
- burden, 99–103
  - behavioral symptoms, 127
- expectation in Nigeria, 128
- impact of dementia on, 172–4
- information from, 8, 64, 65, 68. *See also*
  - informants, proxy
  - Nigeria, 127
- life satisfaction and, 2, 3
- medical attention not sought by, 127, 175
- support for, 172
  - Sweden, 95
  - USA, 95
- support from, 160, 172
  - attitude to old age and, 92
  - China, 108, 111, 150
  - diagnosis and, 128, 133
  - for caregivers, 4, 160
  - lifestyle change and, 2, 4, 108, 113, 159
  - MCI, 18
  - Nigeria, 128–9
  - Peru, 124
  - rural communities, 114
- fatty acids, supplements, 58
- fish oils, 57–8
- fluency, verbal
  - HIV and, 48
  - test, in VCI, 32
- forgetfulness, late life (LLF), 7
- friends
  - life satisfaction and, 2
  - support from, 5, 160
- Frontal Assessment Battery (FAB), 77
- FTD (frontotemporal dementia), 8, 73, 79, 82
- function. *See also* under cognitive
  - CNS and fatty acids, 57
  - cortical, CSI-D measures, 65
- executive
  - apathy/depression and, 77
  - leukoaraiosis, 32
  - MCI, 10
  - VCI, 32
- frontal lobe
  - AD, agitation and, 79
  - VCI, 32
- frontal, executive and subcortical tests, 32



functioning <ul style="list-style-type: none"><li>apathy and, 77</li><li>assessment for AD, 64</li><li>CSI-D assesses, 66–8</li><li>deficits in MCI, 8</li><li>executive<ul style="list-style-type: none"><li>age and, 48</li><li>HIV and, 48</li></ul></li><li>MCI, 8–10</li><li>self-appraisal, 90</li><li>social/occupational, CSI-D measures, 65, 68</li></ul>	Guam, prevalence studies in, 167
funding <ul style="list-style-type: none"><li>agencies, 161</li><li>Australia, 131, 132, 133</li><li>China, 111</li><li>rural areas, 115</li><li>USA, 138</li></ul>	guardians, legal <ul style="list-style-type: none"><li>China, 110, 148</li><li>Japan, 144</li></ul>
GAD (generalized anxiety disorder), 78	Hachinski Ischemic Scale, 41, 42
galantamine, 15, 133, 148	hallucinations, 73, 78, 79 <ul style="list-style-type: none"><li>MCI, 10</li><li>Parkinson’s disease, 81</li></ul>
GBD (global burden of disease), 167, 170	Hamilton Rating Scale <ul style="list-style-type: none"><li>for Anxiety, 75</li><li>for Depression, 75</li></ul>
report, 169	happiness <ul style="list-style-type: none"><li>aspiration in old age, 1</li><li>quality of life and, 92</li></ul>
GDS (Global Deterioration Score), 8, 12, 19	harmonization of test instruments, 65
gender, life satisfaction and, 2	headache in neurocysticercosis, 51
generalized anxiety disorder (GAD), 78	healers, traditional <ul style="list-style-type: none"><li>Nigeria, 127</li><li>role in health care, 2, 3, 108, 109</li></ul>
genetic factors <ul style="list-style-type: none"><li>AD, 28<ul style="list-style-type: none"><li>American Africans, 28</li><li>Yoruba, 28</li></ul></li><li>comparative studies of, 63</li><li>nutrition and, affect cognitive function, 57</li><li>VaD, 39</li><li>VCI, 40</li></ul>	healing, spiritual, 2
Geriatric Depression Scale, 75	health <ul style="list-style-type: none"><li>aspiration in old age, 2</li><li>life satisfaction and, 2, 3</li><li>spirituality and, 2, 3</li></ul>
Geriatric Mental State (GMS), 93, 164	health care <ul style="list-style-type: none"><li>China, 108</li><li>demography and, 1</li><li>family do not seek, 175</li><li>Japan, 141</li><li>roles in Asia, 2, 3</li><li>rural communities, 115</li></ul>
ginkgo biloba, 2, 18	herbal agents, Chinese traditional, 148, 149
global burden of disease (GBD), 167, 170	HIV <ul style="list-style-type: none"><li>AIDS dementia complex, 47</li><li>dementia and, 48–50, 48, 51</li><li>stigma, 47</li></ul>
report, 169	HMG-CoA reductase inhibitors, 49
Global Deterioration Score (GDS), 8, 12, 19	home <ul style="list-style-type: none"><li>help, 5</li><li>support in, 99, 114<ul style="list-style-type: none"><li>Australia, 132</li><li>China, 108, 110, 111</li><li>Japan, 142–3</li><li>lifestyle changes and, 2</li></ul></li></ul>
glutamate antagonists, 148	homes, old people’s <ul style="list-style-type: none"><li>Asia, 4</li><li>Australia, 134</li><li>China, 109, 110</li></ul>
GMS (Geriatric Mental State), 93, 164 <ul style="list-style-type: none"><li>/AGECAT, 65</li><li>effect of education on, 95</li></ul>	
government <ul style="list-style-type: none"><li>education of, 161</li><li>support from, 5<ul style="list-style-type: none"><li>China, 110, 111</li><li>Japan, 141, 143</li></ul></li></ul>	
granulomas, neurological infection, 49, 50, 51	

- homes (cont.)
  - Japan, 142–3
  - staff training, 160
- homocysteine, vitamins and, 56
- homocysteinemia, 38
- Huntington’s disease, 82
- huperzine A, 149
- hydrocephalus, tuberculosis and, 51
- hyperactivity, 80
- hypercholesterolemia, dementia and, 55
- hypertension, 18
  - AD and, 28
  - Asia, 38
  - dementia and, 55
  - VaD and, 37, 38
- identification of ‘famous faces’, in MCI, 10
- imaging. *See also* MRI, PET *etc.*
  - assessment by, 132
  - indices in conversion, 14
  - MCI, 11
  - neurological infection, 49, 50
  - neurotuberculosis, 51
  - VaD, 38
  - VCID, 40
- impact
  - aggression, 79
  - caring, 99–103
  - dementia, 169–74
  - economic, future, 5, 43, 139
  - memory impairment, 15
- incidence
  - dementia, 43, 165, 167
    - 10/66 Dementia Research Group study, 176
    - African Americans, 27
  - depression, caregivers’, 100
  - VaD, 39
- income
  - cardiovascular risk and, 38
  - life satisfaction and, 2, 3
  - national, prevalence of dementia and, 165
- India
  - 10/66 intervention in, 177
  - awareness of dementia in, 174
  - caregivers’ attitudes in, 102
  - dementia and neurological infection, 47–53
  - disability in, 174
  - exercise and health, 2
  - family support in, 172
  - MMSE adapted for, 15, 95
  - prevalence of dementia, 39, 93
  - prevalence studies in, 166, 167
    - 10/66 Dementia Research Group study, 65, 164, 165, 166, 172
  - rural, dementia in, 95
- Indians in Singapore, dementia prevalence, 93
- Indonesia, cognitive tests, 4
- inertia, symptoms of, 75
- infection, opportunistic, in HIV, 49
- inflammatory processes
  - fish oils and, 58
  - MCI, 11
- informants. *See also* caregivers, family, proxy
  - report of symptoms, 75
  - source for diagnosis, 8, 11, 41, 127, 166, 167
    - Australia, 132
- inositols, 149
- insight, loss of, 89
- insomnia, 127
- instrument, assessment
  - CSI-D, 164
  - GMS, 164
- instruments, assessment. *See also* scales, tests
  - 10/66 Dementia Research Group algorithm
    - combines, 65, 93, 124
  - adaptation cross-cultural, 91
  - ADAS-Cog, 132, 133, 149
  - ADRQL, 90
  - CAMCOG, 132
  - CERAD, 65, 164
  - CILQ, 90
  - cross-cultural adaptation, 63–9
  - CSI-D, 64
  - DQoL, 90
  - ECAQ, 4
  - FAB, 77
  - GMS/AGECAT, 65
  - GMS, 93, 95
  - Hachinski Ischemic Scale, 41, 42
  - in VaD, 42
  - IQCODE, 11
  - MCA, 11
  - memory, 4
  - MMSE, 4, 132, 133, 147, 149
  - MSQ, 4
  - NPI, 77
  - quality of life, 88, 89–91
  - SEIQoL, 90

- insurance, care, Japan, 141–3, 144, 145
- intervention programs for caregivers, 100–2, 103
  - 10/66, “Helping carers to care”, 177
- IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly), 11
- irritability, 75, 76, 78
  - MCI, 10
  - scale, 75
- Isaacs Set Test, 14
- isoniazid, 51
- Italy, prevalence studies in, 167
- Jamaica, CSI-D adapted for, 65
- Japan
  - attitude to dementia, 4, 92
  - care in, 141–5
  - demography, 1
  - depression, 3
  - exercise and health, 2
  - prevalence studies in, 166
  - VaD prevalence, 39
- judgment
  - CSI-D measures, 65
  - MCI and, 10
- Kenya, CSI-D adapted for, 65
- Korea
  - attitudes to old age, 92
  - BEHAVE-AD in, 75
  - exercise and health, 2
  - prevalence of dementia, 39
  - prevalence studies in, 166, 167
  - traditional medicine, 2
- LAMIC (low and middle income countries),
  - dementia studies in, 163–76
- Lancet/ADI review of dementia prevalence, 165–6
- language
  - adapting test instruments to a different, 65–9, 164
  - barriers, in health care, 114
  - cognitive domain, 7
  - difficulties, in testing, 133
  - drug effects, 18
  - testing, 66
  - VCI, 32
- LARS (Lille Apathy Rating Scale), 77
- learning
  - cognitive domain, 7
  - HIV and, 48
- legislation, retirement, 1
- leukoaraiosis, 32, 33
- leukoencephalopathy, progressive multifocal, 48
  - HIV and, 50
- Lewy body dementia, 8, 33
- libido, HIV and, 49
- life. *See also* quality of life
  - end of, issues in Nigeria, 129
  - expectancy, 5
    - China, 107
    - dementia prevalence and, 40
    - Peru, 123
  - satisfaction, 2–3
    - determinants, 2
    - therapy and, 120
- lifestyle
  - care to maintain premorbid, 145
  - management, in MCI, 19
  - support for elderly and, 2, 4, 159
- Lille Apathy Rating Scale (LARS), 77
- literacy test, validity and, 4
- LLF (late-life forgetfulness), 7
- longevity
  - and dementia incidence, 159
  - aspiration in old age, 1
  - ginkgo biloba and, 2
- malaria, cerebral, 47
- Malays, dementia prevalence, 39, 93
- Malaysia, cognitive tests, 4
- management
  - agitation/aggression, 78
  - Australia, 133–4
  - caregivers’ education in, 102, 175
  - dementia, 117–20
  - MCI, 15–19, 20
  - Nigeria, 128
- marital status and life satisfaction, 2
- Mayo clinic study of aging and dementia, 11
- MCA (Montreal Cognitive Assessment), 11
- MCI (mild cognitive impairment), 7–10
  - amnesic (a-MCI), 8, 10, 13, 16, 82
  - comparative studies in, 63
  - diagnosis, 19, 20, 64
  - epidemiology, 9, 16
  - features
    - behavioral, 80
    - clinical, 10
  - management, 15–19, 20

Index

- MCI (cont.)
  - multiple-domain (md-MCI), 8, 10, 13, 16
  - pre-, 19
  - predictor
    - of conversion, 11–15, 12, 16
    - of dementia, 20
  - prevalence, 9, 16
  - prognosis, 10
  - symptoms, 78, 82
  - syndrome, 8
  - tests, 10–11
  - vascular pre-dementia, 9
- measurement. *See also* assessment, instruments
  - educational level, 28
  - memory, in MCI, 10
- measures
  - behavioral dysfunction, 75
  - diagnostic, education level and, 124
  - quality of life, 88
- medication
  - Australia, 133
  - China, 148, 149
  - expectations of in Nigeria, 128
  - USA, 138
- medicine, traditional
  - Chinese, 2, 108, 109, 148, 149
  - Korea, 2
  - Singapore, 2
- memantine, 49, 133, 139, 148, 149
- memory
  - age-related changes, 7
  - anxiety and, 78
  - clinic, Australia, 132
  - cognitive domain, 7
  - complaints, prevalence, 9
  - CSI-D measures, 66
  - deficits in MCI, 7–10, 11
  - drug effects, 18
  - HIV and, 48
  - impairment
    - impact, 15
    - measuring, 4
    - therapies, 119
  - measures
    - CSI-D, 65
    - MCI, 10
  - quality of life and, 89
  - VCI, 31
- meningitis
  - dementia caused by, 49
  - tuberculosis and, 50
- meningoencephalitis, tuberculosis and, 50
- Mental Status Questionnaire (MSQ), 4
- Mexico
  - 10/66 intervention in, 177
  - family support in, 172
  - neurocysticercosis, 52
  - prevalence studies in, 167
  - 10/66 Dementia Research Group study, 166, 176
- micronutrients, 177
  - cognitive function and, 56–7
- Mini-Mental State Examination. *See* MMSE
- misidentification, 73, 80
- MMSE (Mini-Mental State Examination), 4
  - anxiety and, 78
  - Australia, 132, 133
  - China, 147, 149
  - cultural factors and, 15
  - Hindi adaptation, 95
  - MCI, 10
  - Parkinson’s disease, 81
  - Peru, 123
  - predictor of conversion, 14
- Montreal Cognitive Assessment (MCA), 11
- mood. *See* depression
  - quality of life and, 89
- morbidity, caregiver, 101
- mortality
  - 10/66 Dementia Research Group study, 176
  - risk, MCI and, 10, 18
- motor
  - behavior, aberrant, 10, 79
  - coordination, MCI and, 10
  - response, testing, 66
  - symptoms
    - AIDS dementia complex, 49
    - MCI, 10, 78
- MRI
  - assessment, 132, 139
  - cognitive decline, 41
  - MCI, 11
  - neurosyphilis, 50
  - predictor of conversion, 14
  - progressive multifocal leukoencephalopathy, 50
- MRS, in MCI, 11
- MSQ (Mental Status Questionnaire), 4
- multidisciplinary care in China, 148

- music therapy, 95, 118, 120
- myoclonus in CJD, 52
- National Institute of Mental Health work group, 7
- neurofibrillary tangles, 79
  - MCI, 11
- neurological infection, dementia and, 47–53
- neuropeptides, 149
- Neuropsychiatric Inventory. *See* NPI
- neurosyphilis, 48
  - AIDS and, 50
  - dementia and, in India, 50
- NGOs, 116
  - role in education and awareness, 153–8, 160–2
  - support from in China, 109, 110
- nicotinamides, 149
- Nigeria
  - 10/66 Dementia Research Group study, 172
  - AD, 64
  - dementia and care in, 127–9
  - dementia incidence and prevalence, 43
- nilvadipine, 18
- nootropics, 18
- Nottingham model of psychogeriatric services, 110
- NPI (Neuropsychiatric Inventory), 74, 75, 77, 78
  - Parkinson’s disease, 81
  - subsyndromes of AD, 80
  - VaD, 80
- nutrition
  - 10/66 Dementia Research Group study, 177
  - dementia and, 47, 55–8
  - Nigeria, 129
- obesity, VaD and, 37
- occupation
  - cognitive reserve and, 19
  - life satisfaction and, 2
- olfaction, MCI and, 20
- Overt Aggression Scale, 75
- paranoia, 75
- Parkinson’s disease, 79
  - dementia, 81, 82
  - rating scales, 77
- parkinsonian features, in AIDS dementia complex, 49
- parkinsonism, apathy and, 77
- pathology
  - cerebrovascular, 43
  - cognitive reserve and, 19
  - conversion to dementia, 20
  - debate over VaD, 41
  - FTD, 82
  - leukoaraiosis, 32
  - MCI, 11
  - neurological infections, 49
  - neurotuberculosis, 51
  - predictor of conversion, 14
  - VaD, 37, 38
  - VCI, 31, 33, 40
- patient, role of, in traditional healing, 2
- penicillin, 50
- peptide T, 49
- Peru
  - 10/66 intervention in, 177
  - dementia and care in, 123–5
  - family support in, 172
  - prevalence studies in, 167
  - 10/66 Dementia Research Group study, 166, 176
- PET
  - assessment, 139
  - MCI, 11
  - predictor of conversion, 14
  - SCI, 20
- pets, 120
- phobias, 75
- phosphatidylserine, 18
- piracetam, 18
- plaques, neuritic, in MCI, 11
- Poland, prevalence studies in, 167
- polioaraiosis, 32
- politicians/policy makers, 154, 156, 161, 175
- population
  - cardiovascular disease and, 38
  - statistics, 1
- Positive and Negative Syndrome Scale, 75
- power of attorney in China, 110
- prevalence
  - AAMI, 10
  - AD, 40
  - agitation, 79
  - apathy, 76
  - CIND, 10
  - dementia, 39, 43–4, 170
    - China, 107
    - choice of criteria influences, 164, 165
    - ethnic differences, 39, 93
    - Lancet/ADI Review, 165–6
    - Peru, 124

Index

- prevalence (cont.)
  - rural India, 95
  - studies, 165–8
  - USA, 137
- depression, caregivers', 100
- HIV, in India, 48
- infection, 47
- MCI, 9, 16
- memory complaints, 9
- symptoms, 73
- VaD, 38, 39–40, 42
  - Japan, 39
- priest, role of in healing, 2
- professionals, health
  - community services, 114–15, 132
  - raising awareness among, 154, 159, 175
- profiles, neuropsychological
  - dementia diagnosis, 48
  - neurosyphilis, 50
- proxy. *See also* caregivers, family, informants reports, 89
- psychometric tests, 66. *See also* instruments, tests
- psychosis, 172
  - AD, 79, 81
  - Parkinson's disease, 81
  - symptoms of, 75
- psychotropics, 134, 148
- Puerto Rico, 10/66 Dementia Research Group study, 166
- pyramidal signs, progressive multifocal
  - leukoencephalopathy, 50
- pyrazinamide, 51
- QoLAS (Quality of Life Assessment Schedule), 90
- quality of life
  - attitude to aging and, 92
  - caregivers', 90, 99, 118
  - determinants of, 73
  - different cultures and, 91
  - health of caregiver and patient's, 100
  - issues affecting, 5
  - measure of care, 143
  - measures, 88
  - scales, translation, 95
  - therapy to improve, 118
    - MCI, 18
- Quality of Life Assessment Schedule (QoLAS), 90
- questionnaires
  - as test instruments, 91
  - cognitive change assessment, 4, 11
- reading, as measure of education, 28
- reality orientation, 119
- recall, delayed, 12
  - MCI, 10
    - predictor of conversion, 14
- rehabilitation therapies in MCI, 18
- religion
  - influences caregivers, 92
  - life satisfaction and, 3
  - perception of old age and, 1
  - role in health care, 2
    - Nigeria, 127
  - stress and, 3
  - support from in Nigeria, 128
- reminiscence therapy, 95, 120, 177
- respect for the elderly
  - differences in, 3
  - effects of, 95, 103, 167
- restlessness, 73
- restraint, physical, 119
- retirement
  - age of, 1, 5
  - legislation, 1
- rifampicin, 51
- risk
  - AD, 28
  - cognitive decline, 28
  - conversion to dementia, 19
  - dementia, 28, 39, 43
    - diet and, 57
    - Peru, 124
  - factors
    - comparative studies, 63, 64–5
    - 10/66 Dementia Research Group study, 177
    - VCI, 34
  - modification, 19, 35
  - stroke, 39
  - vascular disease, 37, 43, 56
    - AD and, 28
    - homocysteine and, 56
    - VaD and, 37, 38
- rivastigmine, 15, 133, 148
- rural communities
  - AD and, in America, 28
  - dementia in, in India, 95
  - dementia services in, 113
    - China, 109, 150
  - services, 113–16
  - support in old age and, 2

- Russia
  - 10/66 Dementia Research Group study, 164
  - 10/66 intervention in, 177
- scales, rating, 75. *See also* instruments
  - AES, 77
  - agitation/aggression, 78
  - apathy, 77
  - Apathy Scale, 75
  - BEHAVE-AD, 75
  - behavioral dysfunction, 75
  - BPSD, 73
  - BRSD, 75
  - Cornell Scale for Depression in Dementia, 75
  - Geriatric Depression Scale, 75
  - Hamilton Rating Scale
    - for Anxiety, 75
    - for Depression, 75
  - LARS, 77
  - multi-linguistic societies, 48
  - NPI, 75
  - Overt Aggression Scale, 75
  - Positive and Negative Syndrome Scale, 75
  - severity
    - CDR, 8
    - dementia, 32
    - GDS, 8
  - validation, 95
  - VCI, 34
  - WHODAS, 166
- Schedule for the Evaluation of Individual Quality of Life (SEIQoL), 90
- schizophrenia, 78, 81
- SCI (subjective cognitive impairment), 19
- screening
  - community, 63, 64, 69
  - instruments or tests
    - cultural factors and, 15, 93
    - ECAQ, 4
    - education and, 124, 164
    - for VCI, 34
    - MMSE, 10
  - interview, 65, 69
- SEIQoL (Schedule for the Evaluation of Individual Quality of Life ), 90
- seizures in neurocysticercosis, 51
- self-appraisal by SEIQoL, 90
- self-esteem, in MCI, 18
- serological studies in neurological infection, 49
- serotonin reuptake inhibitors, 49
- severity
  - AD, symptoms and, 79, 80
  - neuropsychiatric disturbances, 73
- scales
  - CDR, 8
  - dementia, 32
  - GDS, 8
- signs
  - motor in AIDS dementia complex, 49
  - neurological infection, 49
  - neurosyphilis, 50
  - pyramidal, in progressive multifocal leukoencephalopathy, 50
- Singapore
  - caregivers' stress in, 4
  - cognitive tests, 4
  - dementia prevalence, 39, 93
  - demography, 1
  - depression, 3
  - life satisfaction, 2
  - traditional medicine, 2, 3
- sleep disturbance, 80
- sleeplessness, 73
- Smell Identification Test, University of Pennsylvania, 14
- smoking, and VaD, 38
- social protection, 172
- societies
  - different
    - perspectives on dementia
      - affect diagnosis of VaD, 39
    - perspectives on old age
      - affect diagnostic criteria, 15
    - Asia, 1–2, 3
    - multi-linguistic, assessment scales in, 48
- Spain, prevalence studies in, 167
- SPECT
  - AD, 79
  - predictor of conversion, 14
- spirituality
  - health and, 2, 3
  - influences caregivers, 92
  - life satisfaction and, 3
  - quality of life and, 92
  - role in health care in Nigeria, 127

Index

- Sri Lanka, 10/66 Dementia Research Group study, 166
- steroids, prevent cerebral edema, 52
- stigma, 154, 174, 175
  - AIDS dementia complex, 47
  - psychiatric treatment, 4
- streptomycin, 51
- stress
  - caregivers', 4, 118
  - in the elderly, status and, 3
  - oxidative
    - and age, 57
    - DNA and, 58
  - religion and, 3
  - response to, 78
- stroke
  - Asia, 38
  - dementia following, 33
  - fish oils and, 58
  - VaD and, 38–9
  - vascular MCI and, 9
- support. *See also* care
  - community, 5
  - family
    - Asia, 2, 3
    - China, 150
    - for caregivers, 4, 101
    - Korea, 92
    - life satisfaction and, 2
    - lifestyle change and, 159
    - MCI, 18
  - for family/caregiver, 100, 101, 117–18, 154, 175
    - Asia, 4
    - groups, 120
    - Sweden, 95
    - USA, 95
  - friends', life satisfaction and, 2
  - government, 5
  - groups, 120, 128, 154, 175
  - networks, 5
  - religious groups offer, 3, 128
- Sweden, care in, 94
- symptoms
  - behavioral
    - agitated/aggressive, 78–9
    - conversion and, 14
    - HIV and, 48
    - MCI and, 10
    - MCI, 10
  - motor
    - AIDS dementia complex, 49
    - MCI, 10
  - neuropsychiatric, 89
    - MCI, 10, 16
  - Parkinson's disease, 81
  - psychotic, 75
  - vegetative, 75
- syndromes
  - anxious or depressive, 9
  - dementia, 43
  - MCI, 8
  - misidentification and reduplication, 80
  - negative, 77
  - positive and negative, 75
- Tai-chi, 2
- Taiwan
  - prevalence studies in, 166
  - VaD in, 75
- task-switching capacities in MCI, 10
- tests. *See also* instruments
  - clock-drawing, 11
  - cognitive
    - factors influencing, 64
    - HIV, 48
    - validity, 4
  - frontal, executive and subcortical function
    - HIV, 48
    - VCI, 32
  - neurological infection, 50
  - neuropsychological
    - assessment for AD, 65
    - education and, 28
    - MCI, 10, 19
  - psychometric, 66
  - screening, cognitive impairment, 4, 10
- Thai Mental State Examination (TMSE), 79
- Thailand
  - activities of daily living, 79
  - prevalence studies in, 167
- therapies
  - creative arts, 95, 118, 120
  - in MCI
    - behavior, 18
    - pharmaco, 15
    - rehabilitation, 18



- management, 117–20
- occupational
  - MCI, 18
- thinking
  - cognitive domain, 7
  - CSI-D measures, 65
- tiredness, excessive, HIV and, 49
- TMSE (Thai Mental State Examination), 79
- tolerance
  - of care burden
    - India and China, 103
  - of symptoms
    - America, 76
    - Australia, 73
    - China, 73
    - Chinese, 76
- touch, therapeutic, 119
- toxoplasmosis, 48
  - HIV and, 49
- trailmaking test in VCI, 32
- training. *See* education
- translation
  - in assessment, 94
  - of rating scales, 95
  - of test instruments, 65, 66, 91, 164
- treatment
  - disease-modifying, 139
  - evaluation, ADRQL, 90
  - neurotuberculosis, 51
- tuberculosis, 48
  - as differential diagnosis, 47
  - CNS, 50
- Turkey, prevalence studies in, 167
- Unified Parkinson’s Disease Rating Scale, 81–2
- urban communities
  - access to care in, 114
  - AD and, in America, 28
  - support in old age and, 2
  - VaD and, 38
- USA
  - AD and dementia, 27–9, 139
  - care in, 94
  - dementia, 27
  - criticism of concept of, 40–4
  - etiology, 33
  - NPI in, 75, 80
  - prevalence, 39, 40, 42, 107
    - ethnicity and, 93
    - USA, 137
  - stroke and, 38–9
- validation therapy, 119
- validity
  - concept of VaD, 40–4
  - dementia diagnosis, 163–5
    - 10/66 dementia diagnosis, 177
  - predictive, 165, 167, 177
  - rating scale, 95
  - relatives’ assessments, 68
  - test, 4, 19, 91
  - test instruments across cultures, 91
- vascular
  - cognitive impairment. *See* VCI
  - dementia. *See* VaD and VCI
  - disease
    - AD and, 28
    - behavioral symptoms, 81
    - cognitive decline, 56
    - homocysteine and, 56
    - VaD and, 38
  - health, fish oils and, 58
- vasodilators, 149
- VCI (vascular cognitive impairment), 31–5, 40, 42. *See also* VaD
  - NPI in, 81
- Venezuela
  - prevalence studies in, 167
    - 10/66 Dementia Research Group study, 166, 176
  - 10/66 intervention in, 177
- visuospatial
  - functioning, cognitive domain, 7
  - impairment
    - AD and, 79
    - HIV and, 48
    - MCI and, 10
- vitamins
  - cognitive function and, 18, 56–7
  - questions over, 133, 148
- wandering, 73, 127
- wealth, aspiration in old age, 1
- VaD (vascular dementia), 31. *See also* VCI
  - Asia, 80

Cambridge University Press  
978-0-521-85776-5 - Dementia: A Global Approach  
Edited by Ennapadam S. Krishnamoorthy, Martin J. Prince and Jeffrey L. Cummings  
Index  
[More information](#)

Index

WHODAS (WHO disability scale), 166

World Alzheimer Report 2009, 167–9, 170

World Alzheimer’s Day, 155, 161

World Health Organization

CARITAS, 113

Mental Health Gap Action Plan, 176

yin and yang, 2, 3, 149

Yoruba

comparative studies in, 64

CSI-D adapted for, 65

genetic factors for AD, 28

vascular disease, 28